cyte recruitment and retention, as well as the formation of foam cells and thrombi (for a review see 2) ). Macrophages internalize and degrade oxLDL mainly through scavenger receptors, and one crucial step in the initiation and progression of atherosclerosis is the unregulated uptake of oxLDL through these receptors, leading to foam cell formation 2) . Another receptor, named lectin-like oxLDL receptor-1 (LOX-1), is expressed in all cell types involved in the atherosclerotic lesion, i.e. endothelial cells (ECs), macrophages, and smooth muscle cells (SMCs) 3) . LOX-1, a membrane glycoprotein that binds oxLDL and acetylated LDL (AcLDL) but not native LDL 4, 5) , differs from the macrophage scavenger receptors because it contributes to the atherosclerotic process mainly through receptor-mediated signaling mechanisms
Introduction
Atherosclerosis is a multifactorial disease of the vessel wall involving lipid accumulation, thrombogenic components, cell death and inflammatory responses in the arterial wall, causing heart disease and stroke 1) . Modification of low-density lipoprotein (LDL) in the arterial wall, particularly by oxidation, is crucial to the cellular uptake of LDL in the early stages of atherosclerotic plaque development 2) . Oxidized LDL (oxLDL) is involved in the very early critical steps of atherogenesis, such as endothelial injury, expression of adhesion molecules, and leuko-and bacteria [7] [8] [9] [10] , implying versatile physiological functions. This review specifically focuses on the structure, regulation and ligands of LOX-1 and highlights the mechanisms by which LOX-1 activation contributes to atherosclerosis.
The activation of LOX-1 triggers intracellular signaling, production of superoxide radicals and gene expression induced by the redox-sensitive transcription factor NF-B which plays a key role in these processes 11) . In 2000, the same research group that revealed the presence of LOX-1 in vascular tissue 12) discovered the soluble form of this membrane receptor, named soluble LOX-1 (sLOX-1), showing that it derived from membrane-bound LOX-1 itself 13) . The crucial role of LOX-1 in the atherosclerotic process 14) highlighted this receptor as a logical and attractive candidate for therapeutic intervention to limit vascular damage and its long-term consequences, although several key questions have not yet been answered. Here we provide a critical review of the recent literature on this receptor and likely future directions.
LOX-1 Gene: Structure, Polymorphism and Alternative Transcripts
Gene Structure LOX-1 is encoded by the oxLDL receptor 1 (OLR1) gene, located in the natural killer gene complex (NKC) on chromosome 12 at p12-p13, which also contains several other families of lectin-like genes, including the CD94 and NKG2 NK receptor genes 15) . The region telomeric of CD94 contains in addition to the LOX-1 gene, the novel human DECTIN-1 and the CLEC-1 and CLEC-2 genes within about 100 kb. Sequence similarities and chromosomal arrangement suggest that these genes form a separate subfamily of lectin-like genes within the NKC encoding receptors with important immune and/or scavenger functions in monocytes, dendritic cells and EC 16, 17) . The OLR1 gene spans more than 7000 base pairs (bp), and consists of 6 exons interrupted by 5 introns; exons 1 − 5 range from 102 to 246 bp, whereas exon 6 is relatively long, being 1722 bp (Fig. 1) . Exon 1 encodes the 5'-untranslated region (UTR) and cytoplasmic domain, exon 2 encodes the remainder of the cytoplasmic domain and the transmembrane domain, exon 3 encodes the neck domain, and exons 4, 5 and 6 encode the lectin-like domain and the 3'-UTR of LOX-1 protein 15, 18) (Fig. 1) (as better described in the section "protein structure of LOX-1"). The 5' promoter/ enhancer region (about 2500 bp) of the human OLR1 gene was also studied, and TATA and CAAT boxes were found in the proximal part of the 5'-flanking region. Computer-based analysis identified a wide variety of potential transcription factor-binding sites, including sites for the STAT family and NF-interleukin (IL)-6 15, 19) . The transcriptional repressor octamer-1-binding site within the promoter region plays an important role in the human LOX-1 promoter trans-activation in response to oxLDL. Furthermore, the promoter region between nucleotides-2131 and -2247, which includes an active NF-B-binding site, is required for angiotensin (Ang )-induced transactivation of the human LOX-1 promoter 20) .
Gene Polymorphisms and Splicing Variants
Some studies have shown common genetic variation in the OLR1 gene to be associated with the risk of coronary artery disease (CAD). Three common LOX-1 single nucleotide polymorphisms (SNPs) have been identified in intron 4 (G A), intron 5 (T G) and 3'UTR (T C) 21) . Contemporaneously, the involvement of LOX-1 in atherosclerosis and acute myocardial infarction (AMI) was confirmed by defining OLR1 genetic variation in an association study of intragenic SNPs 22) . Seven SNPs were identified of which six were within intron 4, intron 5, and the 3' UTR. These six polymorphisms were in complete linkage disequilibrium behaving as a single SNP block, including exon 5.
It was observed that the LOX-1/3'UTR SNP genotype and allele frequencies differed significantly between the control and the AMI groups in which the subjects with the T/T or C/T genotype were at higher risk of developing AMI 22) . Despite the positive results on OLR1 polymorphisms in CAD or AMI subjects [22] [23] [24] , other similar studies were unable to confirm these putative genetic risks [24] [25] [26] . In particular, regarding a functional SNP, the G C transition at position 501 in exon 4 which produces a single amino acid change (K167N) in the ligand-binding domain and affects markedly LOX-1 receptor activity 27) , different conclusions have been reported [22] [23] [24] [25] [26] . Furthermore, it has been explored whether the SNPs could give rise to a functional product by examining the existence of messenger RNA (mRNA) isoforms as a consequence of alternative splicing 28) . A reproducible pattern of alternative splicing in the OLR1 gene around exon 5, with 2 resulting OLR1 transcripts in the RNA fractions, was identified: one of these products corresponded to the full-length transcript, while the other (named LOXIN) lacked exon 5. The LOXIN spliced mRNA has a stop codon in the open reading frame that leads to a premature termination of the translation product and generates a protein that lacks 2/3 of the lectin-like domain and is unable to bind oxLDL 28) . Experiments both in vivo and in vitro indicate that the splice variant LOXIN is expressed at a similar level to the full-length receptor LOX-1, and their relative transcription is modulated by the presence of SNPs 28) . Macrophages from subjects carrying the "nonrisk" haplotype expressed more LOXIN and so fewer cells underwent apoptosis on oxLDL induction 28) . Therefore, higher levels of LOXIN protect cells from LOX-1-induced apoptosis. Also LOXIN tends to dimerize, therefore its protective role may be due to inactivation of the LOX-1 receptor via the formation of a heterodimer 28) . Molecular LOX-1/LOXIN interaction and the formation of non-functional heterooligomers have been recently confirmed 29) , suggesting hetero-oligomerization between naturally occurring isoforms of LOX-1 to represent a general model for the regulation of LOX-1 function by its variants.
It is difficult to draw definite conclusions from these conflicting studies; multiple large, well-matched cohorts of cases and controls will be required to achieve valid progress in the genetic analysis of atherosclerosis and other complex human diseases indicating mostly the need for caution in the interpretation of genetic associations.
Protein Structure of LOX-1
LOX-1 has a molecular weight of 50 kDa and is a type membrane protein belonging to the C-type lectin family 12) . LOX-1 is synthesized as a 40-kDa precursor protein, subsequently glycosylated at four potential N-linked glycosylation sites in the extracellular C-terminal domain, and processed into a 48-kDa mature form within 40 min 30) . LOX-1 consists of four domains: a short N-terminal cytoplasmic domain, a single transmembrane domain, a connecting stalk region (neck) domain, and a lectin-like extracellular domain at the C-terminus which binds oxLDL 12) (Fig. 2) . The extracellular part of LOX-1 comprises an 82-residue neck and a ligandbinding domain. A coiled-coil structure is located in the C-terminal part of the neck, and is in dynamic equilibrium among multiple conformational states. This chimeric structural property of the neck region may enable LOX-1 to cluster at the cell surface, where it exists as a homodimer to recognize oxLDL 31, 32) . One-third of the N-terminal neck is less structured than the remainder of the protein and is highly sensitive to cleavage by a variety of proteases 32) . Both positively charged and non-charged hydrophilic residues are involved in ligand binding, suggesting that ligand recognition of LOX-1 depends on more complex conformational interactions, rather than merely electrostatic interaction between positively charged residues and negatively charged ligands 33) . LOX-1 also exists as a soluble form (sLOX-1), corresponding to its extracellular domain only 13) . Two soluble forms of similar molecular weight (approximately 35 kDa) were identified in the supernatant of bovine aortic EC 13) . In tumor necrosis factor-(TNF-)-activated cells, cell-surface expression of LOX-1 precedes sLOX-1 release 13) which is inhibited by serine protease inhibitors, particularly by PMSF 13) . Nevertheless, it has been recently shown that overexpression of ADAM10, a member of the disintegrin and metalloproteinase family, enhanced the cleavage of sLOX-1 while its inhibition suppressed it, suggesting the effect of PMSF on sLOX-1 production to be indirect 34) . Purification and sequencing of bovine sLOX-1 identified the two cleavage sites between Arg(86)-Ser (87) and Lys(89)-Ser(90), which were located in the membrane proximal extracellular domain of LOX-1 13) . It has been further shown that IL-18 stimulated the shedding of LOX-1 and subsequent release of sLOX-1 34) . A circulating soluble form of LOX-1, corresponding solely to its extracellular domain, has been identified in human serum, as we will discuss in detail afterwards.
Regulation of LOX-1 Expression
The LOX-1 promoter is constitutively active only at a low level though its expression can be induced by oxLDL 35, 36) , fluid shear stress 37) , Ang 20) , proinflammatory cytokines 4, 19, 38) , lipopolysaccharide 38) , phorbol 12-myristate 13-acetate (PMA) 4) , oxidants 39) , fluid shear stress, heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) 40) and others ( Table 1) .
In ECs, glycoxidized LDL and oxLDL significantly increase LOX-1 expression and the production of sLOX-1, although the effect of glycoxidized LDL is greater than that of oxLDL 41) . In addition in the same cells, advanced glycation endproducts (AGEs), C reactive protein (CRP), high glucose and IL-6 induce expression of LOX-1 [42] [43] [44] . Furthermore, lysophosphatidylcholine, the main phospholipid component of oxLDL, as well as super- Tumor necrosis factor- 4, 19, 38) Phorbol 12-myristate 13-acetate 4) Fluid shear stress 37, 38) OxLDL 35, 36) Lysophosphatidylcholine 36, 45) Angiotensin 20) Transforming growth factor- 47) High glucose concentration [42] [43] [44] 52) Norepinephrine 50) Endothelin-1 50) Oxidant species 39) Homocysteine 39) C reactive protein 43, 44) HB-EGF 40) IL-6 43, 44) , IL-1 19) , IL-1 19) Remnant-like lipoprotein particles 49) Advanced glycation endproducts 42) Glycoxidized LDL 41) oxide anions, hydrogen peroxide and homocysteine up-regulate the expression of LOX-1 mRNA 36, 39, 45) . Also endothelin-1 (ET-1) stimulates endothelial LOX-1 expression in a receptor-mediated manner 46) . Transforming growth factor-, which plays a crucial role in vascular remodeling and the pathogenesis of atherosclerosis, induces the expression of LOX-1 in both EC and SMCs 47) . In this latter cell type, the mediators of the inflammatory acute phase response (IL-1 , IL-1 and TNF-) regulate the expression of LOX-1 19) . In addition, in SMCs, LOX-1 acts as a receptor for remnant-like lipoprotein particles (RLPs) that up-regulate its expression and induce cell migration, suggesting a proatherogenic role, especially in the settings of postprandial hyperlipidemia, diabetes and metabolic syndrome 48, 49) . LOX-1 expression in cardiac myocytes, as well as in vessel walls of failing rat hearts in vivo, is induced by neurohormonal factors activated in heart failure such as norepinephrine and ET-1 50) . In this regard, since increased protease activity is a key feature of plaque instability that may achieve an enhancement of sLOX-1 release, cardiac myocytes, may be another source of sLOX-1 50) . In macrophages, the expression of LOX-1 can be up-regulated by TNF-and high glucose concentrations 51, 52) . In summary, a number of proinflammatory and proatherothrombotic factors are therefore able to regulate the expression of this receptor, suggesting LOX-1 to have an important role in amplifying local inflammatory responses during atherosclerotic development.
LOX-1 as a Multi-Ligand Receptor with High Specificity for OxLDL: is it a Multifunctional Environmental Sensor or an Endocytic Receptor ?
LOX-1 has interesting specificity because it binds oxLDL and with lower affinity, AcLDL, while it does not bind native LDL 5, 53, 54) . In spite of this specificity, LOX-1 recognizes multiple ligands including hypochlorite-modified high density lipoprotein 55) , aged red blood cells, apoptotic cells 7) , leukocytes 56) , activated platelets, bacteria 8, 9) , phosphatidylserine 57) and AGEs 58) suggesting a versatility of function for LOX-1 under pathophysiological conditions in vivo (Fig. 2) . AGEs are well-known ligands for receptor for AGEs (RAGE) but also for other scavenger receptors, including LOX-1, whose binding was effectively suppressed by an anti-LOX-1 antibody 58) . Moreover, LOX-1 has been identified as an additional receptor for endocytic uptake of heat shock protein 70 (HSP70), chaperoned peptides and CRP [59] [60] [61] . As LOX-1 recognizes and binds activated platelets, exposure of LOX-1 on the activated platelet surface assists thrombosis as demonstrated by the accumulation of LOX-1 protein at sites of thrombi in atherosclerotic plaques 62) . Its broad range of ligands in part overlaps with that of other scavenger receptors and toll-like receptors, and implicates LOX-1 in innate immunity, although its precise role in this immunological context has yet to be determined.
The negative charge on ligands is crucial to recognition by LOX-1. In fact, substitution of basic with neutral amino acids greatly decreases the binding capacity of LOX-1. The crystal structure of LOX-1 revealed the ligand-binding interface to be hydrophobic except for the basic spine, which is composed of arginine residues 5) . Experiments with mutated LOX-1 revealed that the substitution of a single amino acid in the basic spine, resulted in the greatest loss of affinity for AcLDL 5) . The ligand-binding domain of LOX-1 has a homodimeric structure with an intermolecular disulfide bond 5) . A single amino acid substitution in the interface caused a severe reduction in binding activity, suggesting the correct arrangement of the dimer to be crucial for binding to oxLDL. Site-directed mutagenesis indicated that cysteine 140 has a key role in the formation of disulfide-linked human LOX-1 dimers 31) . LOX-1 assembles on the cell surface as at least a hexamer comprising three homodimeric LOX-1 molecules in binding to oxLDL 31) . Comparing the size of the dimer surface of LOX-1 (70 Å) with the diameter of LDL (250 Å), it seems plausible that LOX-1 binds to oxLDL as an assembly protein 5) . Furthermore, amphipathic -helices on LDL can act as multiple binding sites for LOX-1 assembly on the cell surface 5) . It is reasonable to think that circulating plasma sLOX-1 is still able to bind oxLDL; however, since the amount of sLOX-1 in circulation is very low, it does not affect oxLDL plasma levels and so could not act as a decoy for oxLDL.
Macrophages use scavenger receptors to internalize and degrade modified LDL, producing foam cells. LOX-1 was detected on human and mouse macrophages, but not on monocytes 51, 63) and the expression of LOX-1 can be induced in human monocytes after macrophage-like differentiation in vitro 63) . In macrophages, LOX-1 expression appears to be regulated differently from CD36 and SR-A expression 64) . Based upon studies with gene-knockout (KO) mice, CD36 and SR-A play crucial roles in macrophage apoptosis and determining the complexity of atherosclerotic lesions 65) . LOX-1 may play significant roles when macrophages 322 are stimulated by atherogenic lipids or proinflammatory stimuli in atherosclerotic plaques 66) . Recently, using LOX-1 KO mice, it has been shown that there was no difference in uptake or degradation of oxLDL in macrophages from wild-type and LOX-1 KO mice and no difference in the rate of clearance of oxLDL from plasma in vivo 66) . However, when expression of LOX-1 was induced with lysophosphatidylcholine, oxLDL uptake and degradation increased 2-fold in wild-type macrophages but did not change in LOX-1 KO macrophages, suggesting that in proinflammatory conditions in which macrophage LOX-1 expression can increase, the oxLDL uptake could substantially increase 66) . Recently it has been shown that LOX-1 is constitutively internalized from the plasma membrane and thus likely to mediate oxLDL trafficking in vascular tissues 67) . Given the many disparities between studies in vitro and in vivo, it remains likely that this receptor is a multifunctional sensor but also an endocytic receptor. However, how it can facilitate intracellular signaling during trafficking of the receptor-ligand complex along the endocytic pathway is not known. Alternatively, it may be that there is diversity of function depending on cell and tissue type, and availability of ligands.
Signal Transduction Pathways Triggered by Ligand-LOX-1 Interaction
LOX-1 is expressed in most cell types relevant to the development of atherosclerotic plaques (i.e., ECs, SMCs, macrophages), and the interaction of LOX-1 with its ligands modifies the cell phenotype in a proatherogenic sense, so that the cells become dysfunctional and more prone to death 68) ( Table 2 ). The identification of LOX-1 as the major receptor for oxLDL in ECs has provided a new clue about the mechanisms by which oxLDL are involved in vessel wall injury.
Most information about LOX-1 signal transduction pathways on EC comes from the activation or inhibition of LOX-1 by oxLDL and LOX-1 antibody respectively. OxLDL has dual effects on cultured cells depending on its concentration and the exposure time: at a lower concentration (from 5 to 10 g/mL) and shorter exposure time it induces proliferation, whereas at a higher concentration (from 50 to 300 g/mL) and longer exposure time it induces apoptosis in ECs, macrophages, and SMCs 69) , and even necrosis 70, 71) ( Fig. 3) . Low concentrations of oxLDL cause the activation of protein kinaseC-(PKC-) 72) , generate low levels of reactive oxygen species (ROS) and promote angiogenesis through an increase in vascular endothelial growth factor (VEGF) via LOX-1-mediated redoxsensitive signaling pathways 73, 74) . OxLDL induces ROS production via NADPH oxidase 75, 76) and downstream alterations include activation of p38 mitogen-activated protein kinase (p38MAPK), a component of oxidant stress-sensitive signaling pathways, phosphatidylinositol-3-kinase, and extracellular-signal-regulated kinase (ERK1/2), which leads to activation of the transcription factor NF-B 35, 77, 78) (Fig. 3) . OxLDL also represses DNA binding of the transcriptional regulator nuclear factor 1, diminishes mRNA levels of monooxygenase cytochrome P450 and decreases production of endothelial-derived hyperpolarization factor, a key regulator of vascular tone 75, 76) (Fig. 3) . Furthermore, oxLDL induces the endothelial expression of plasminogen activator inhibitor-1, implicated in atherothrombosis, through ERK1/2 activation 79) . Furthermore, the binding of oxLDL to LOX-1 decreases intracellular NO levels through increased production of O 2 , which could inactivate NO itself 73, 80) . OxLDL treatment enhances the expression of vascular cell adhesion molecule 1 (VCAM-1), intercellular cell adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein 1 (MCP-1) and selectins, leading to monocyte attachment and activation 81) . The notion that oxLDL mediates these effects via LOX-1 is borne out by the finding that antisense 75) Increased intracellular oxidative stress 73) Induction of apoptosis 35) Induction of proliferation and angiogenesis by increasing VEGF expression 70, 71, 74) Increased expression of adhesion molecules (VCAM-1 , ICAM-1 , Selectins) 81) Increased expression of monocyte chemoattractant protein-1 81) Induction of plasminogen activator inhibitor-1 79) Reduction of endothelial nitric oxide synthase 72, 83) Release of matrix metalloproteinases 72, 83) Smooth muscle cells Induction of apoptosis 86) Monocytes Induction of monocyte adhesion and activation 44) Increased oxLDL uptake and foam cell formation 52) Vascular endothelial growth factor; Vascular cell adhesion molecule-1; Intercellular cell adhesion molecule-1.
LOX-1 mRNA decreased LOX-1 expression and subsequent adhesion molecule expression 81) . However, recently it has been shown that LOX-1 is involved in redox-sensitive, Akt/eNOS and Ca 2 signaling pathways caused by the attachment of monocyte to EC and the blockade of LOX-1 by antibody or small interfering RNA inhibited the monocyte adhesiontriggered signaling pathway in ECs independent of the oxLDL-LOX-1 axis 82) . The binding of oxLDL to LOX-1 induces a reduction in endothelial nitric oxide synthase (eNOS) expression, increases levels of matrix metalloproteinase (MMP) 1, MMP 3 and MMP 9 and collagenase activity, but does not increase the expression of tissue inhibitors of MMPs 72, 83) . Recently, a study provided evidence that in ECs, the membrane type 1-MMP (MT1-MMP), which is involved in atherogenesis, colocalizes and forms a complex with LOX-1 84) . Since the blockade of LOX-1 or MT1-MMP prevented the oxLDL-induced RhoA-dependent downregulation of eNOS protein expression, Rac1-mediated NADPH oxidase activity, and generation of ROS, the LOX-1-MT1-MMP axis may play a crucial role in the small GTPase RhoA and Rac1 activation signaling pathways 84) . Recently, from a cDNA microarray analysis performed in a EC line over-expressing LOX-1 and treated with oxLDL, LOX-1-dependent changes in gene expression associated with inflammation, and the induction of mRNA expression for a number of cytokines, including IL-8, cell adhesion, and signal transduction, were confirmed 85) . In addition, a promoter analysis of the genes that changed following oxLDLmediated LOX-1 activation identified EGR1 and CREB as potential novel transcription factors that function downstream of LOX-1 85) . In SMCs, oxLDL at high concentrations induces apoptosis by increasing the Bax/Bcl-2 ratio 86) , and in EC, oxLDL decreases the expression of the antiapoptotic protein Bcl-2, induces the release of cytochrome C and Smac from mitochondria into the cytoplas- oxLDL-LOX-1 interaction may lead to endothelial dysfunction and/or apoptosis. Low concentrations of oxLDL induce the generation of ROS by activation of NADPH oxidase and PKC-. ROS activate the ERK1/2-MAPK and PI3K pathways, leading to NF-B's nuclear translocation. Consequently, a reduction in eNOS expression and NO's release, an increase in adhesion molecule (VCAM-1, ICAM-1 and selectins) expression, and enhanced release of MCP-1 and MMPs, lead to endothelial dysfunction. The activation of LOX-1 could also decrease cytochrome P450 (CYP450) protein levels resulting in diminished levels of endothelial-derived hyperpolarization factor (EDHF). High concentrations of oxLDL cause diminished Akt gene transcription and an enhanced bax/bcl-2 ratio leading to apoptosis via the release of cytochrome c and Smac from mitochondria to the cytoplasmic compartment, and through activation of caspase-9. mic compartment, and activates caspase-9 87) (Fig. 3) . Decreased eNOS and Bcl-2 expression, together with induction of MMP collagenase activity, resulted in EC injury, dysfunction, and apoptosis (Fig. 3) . The proapoptotic effects of oxLDL are mediated by its receptor LOX-1, because pretreatment of ECs with antisense-LOX-1, but not sense-LOX-1, blocked these effects 87) . Other evidence has shown that CRP also binds to endothelial LOX-1 resulting in the adhesion of monocyte to ECs and increases oxLDL uptake, so contributing to endothelial dysfunction 44, 88) . In cardiac myocytes, activation of LOX-1 by oxLDL induced apoptosis via activation of p38MAPK, which could be blocked by an antioxidant catalase 50) . In chondrocytes, the binding of oxLDL with LOX-1 markedly increased VEGF mRNA expression and protein release through activation of peroxisome proliferator-activated receptor-(PPAR-), suggesting that LOX-1 signal transduction pathways also lead to PPAR-activation 89) .
Lessons from Animal Studies
Several animal models have been developed to dissect the contribution of LOX-1 to the pathogenesis of vasculopathy in pro-atherogenic settings including hypertension, hyperlipidemia, diabetes and mainly atherosclerosis 90) . Its expression is dramatically up-regulated in the aorta in hypertensive rats, suggesting a potential role for LOX-1 in the pathogenesis of hypertension 38) . In addition, LOX-1 overexpression in hypertensive animal models is localized to vascular ECs, which is compatible with the hypothesis that LOX-1 is related to endothelial dysfunction in hypertension 39, 91) . In rats with streptozotocin-induced diabetes, LOX-1 expression was markedly up-regulated in ECs, especially in bifurcations of artery branches from the aorta 43) . In rats with ischemia-reperfusion (I/R) injury, LOX-1 expression was up-regulated, which through p38MAPK activation increased the expression of MMP-1 and adhesion molecules 92) . Furthermore, increased LOX-1 expression in I/R was associated with lipid peroxidation and apoptosis, a large infarcted area, and a loss of left ventricular function 93) . The generation of transgenic and KO mice has elucidated the pathogenic role of LOX-1 in atherosclerosis. LOX-1 KO mice fed a high-cholesterol diet show decreased oxLDL-binding to the aortic endothelium and a preservation of endothelium-dependent vasorelaxation after treatment with oxLDL 94) . The cross-breeding of LOX-1 KO mice with LDL receptordeficient (LDLr KO) mice led to a reduction in atherogenesis compared with LDLr KO mice. Proinflammatory signals, the expression of NF-B and inflammatory markers were increased in LDLr KO mice, but not in double KO mice. Furthermore, LOX-1 KO mice had greater levels of eNOS while in the LDLr KO mice, there was a marked reduction in eNOS expression and its restoration with LOX-1 deletion 94) . Thus, the deletion of LOX-1 sustains endothelial function leading to a reduction in atherogenesis in association with a reduction in proinflammatory and pro-oxidant signals. Conversely, LOX-1 transgenic mice overexpressing LOX-1 but lacking apoE displayed accelerated intramyocardial vasculopathy, and a 10-fold increase in atheroma-like lesion area compared with non-transgenic littermates after 3-weeks on a high-fat diet 95) . Wild-type mice subjected to I/R developed a marked decrease in left ventricular systolic pressure and an increase in left ventricular end-diastolic pressure following I/R, and the degree of change was much less in the LOX-1 KO mice, indicating preservation of left ventricular function with LOX-1 deletion 96) . There was evidence for marked oxidative stress (NADPH oxidase expression, malondialdehyde and 8-isoprostane) and increase of collagen deposition, fibronectin and osteopontin expression following I/R in wild-type mice, but much less so in LOX-1 KO mice 96) . Furthermore, I/R in LOX-1 KO mice resulted in a significant decrease in myocardial injury as well as in the accumulation of inflammatory cells in I/R myocardium and lipid peroxidation 97) . The phosphorylation of p38MAPK and PKB/Akt-1, as well as inducible NOS, was enhanced during I/R in wild-type mice, but much less so in LOX-1 KO mice. These findings provide convincing evidence that LOX-1 is a key modulator of cardiac remodeling which starts immediately following I/R, and its effect is mediated by pro-oxidant signals 97) . Many studies have investigated the relationship between LOX-1 expression and plaque instability.
LOX-1 is extensively expressed in the new blood vessels in the core of human carotid advanced atherosclerotic lesions and colocalized with apoptotic cells, which are present mostly in the rupture-prone regions of atherosclerotic plaques 6, 98) . In hypercholesterolemic rabbits, LOX-1 expression was more prominent in atherosclerotic plaques with a thinner fibromuscular cap and was localized to the macrophage-rich lipid core 99) . Moreover, in the same areas, LOX-1 expression was positively correlated with tissue factor expression and apoptosis, suggesting the involvement of LOX-1 in the destabilization and rupture of atherosclerotic lesions and the subsequent formation of thrombi 100) . Since LOX-1 could be implicated in vascular cell dysfunction related to plaque instability, it has been investigated as a potential target for an imaging tracer of atherosclerosis. In a recent study 101) , AMI-prone Watanabe heritable hyperlipidemic rabbits and control rabbits were injected intravenously with (99m)Tc-LOX-1-mAb. Imaging clearly visualized the atherosclerotic aortas; the level of (99m)Tc-LOX-1-mAb accumulation in unstable plaques was higher than that in neointimal lesions or other, more stable lesions and therefore nuclear imaging of LOX-1 expression with this tracer may be a useful means of identifying atheromas at high risk of rupture. However, in the absence of suitable animal models of vulnerable plaques, we are far from suggesting that LOX-1 is involved in the destabilization of atherosclerotic plaques.
From Bench to Bedside: from LOX-1 to sLOX-1
Several clinical studies have investigated the significance of serum sLOX-1 concentrations in several pathological conditions, particularly vascular disease and diabetes.
The first clinical study to highlight sLOX-1 as a marker in cardiovascular disease dates back to 2005 102) . In this study, serum sLOX-1 levels were elevated in acute syndrome coronary (ACS). Serum sLOX-1 levels did not show any correlation with troponin-T or creatine phosphokinase levels, suggesting that sLOX-1 is not a marker for cardiac necrosis or injury 102) . A clinical study carried out on patients with ACS reported an association of serum sLOX-1 levels with the severity of CAD and urinary 8-isoprostane levels and an inverse correlation with extracellular superoxide dismutase levels suggesting that increased serum sLOX-1 levels reflect enhanced oxidative stress in vascular walls 103) . In type 2 diabetic patients, serum sLOX-1 levels were higher compared with controls 42) . Serum sLOX-1 decreased after improvements in glycemic control and the magnitude of this reduction correlated with the improvement in hemoglobin A1c and AGEs but not with the reduction in oxLDL 42) . Recently, we reported that sLOX-1 levels were increased in CAD patients and associated with the severity of CAD and inflammatory markers 104) . Other recent data showed that obese women have higher sLOX-1 levels, which may reflect increased LOX-1 expression in adipose tissue 105) . Recently, a likely relationship between LOX-1 gene polymorphisms and circulating sLOX-1 levels has been reported. The 3'UTR-T allele was associated with lower sLOX-1 levels in healthy older subjects suggesting LOX-1 gene variation to be important in the regulation of sLOX-1 levels in plasma 106) . Since association studies aiming to link metabolic and cardiovascular disease with sLOX-1 are far from conclusive due to over or misinterpretation of associations and supposed correlations, the clinical relevance of these observations needs to be assessed in extended clinical trials.
Drug Modulation of LOX-1 Expression
Several drugs commonly used in the treatment of type 2 diabetes, hypertension and hypercholesterolemia, appear to inhibit LOX-1 expression 107) . In hypertensive rats, and in cultured glomerular cells, not only antihypertensive drugs but also antioxidants suppressed LOX-1 overexpression 108) . PPAR activators inhibited TNF--and PMA-induced LOX-1 mRNA overexpression in cultured ECs, but PPAR activators did not. In addition, thiazolidinedione pretreatment suppressed the renal LOX-1 expression induced by intraperitoneal TNF-in mice 91) , thus, the anti-atherogenic effect of PPAR ligands appears to be at least partially mediated through LOX-1. Furthermore, in cultured ECs the PPAR ligand pioglitazone inhibited LOX-1 expression and monocyte adhesion in a fashion similar to an antisense probe to LOX-1 mRNA 109) . It is not excluded that the inhibitory effect of PPAR ligands on LOX-1 expression may be exerted through their antioxidant effect 91) . In SMCs, LOX-1 expression induced by IL-1 was decreased by the PPAR activators as well 19) . Treatment with losartan, an antagonist of Ang , attenuated aortic intimal proliferation in rabbits on a high-cholesterol diet and markedly decreased LOX-1 expression 110) . Reinioside C, the main component of Polygala fallax Hemsl, which has putative antihyperlipidemic properties, inhibited oxLDL-induced LOX-1 mRNA and protein expression 111) . Mulberry leaf aqueous extracts had potential antioxidative effects, and inhibited LOX-1 m-RNA and protein expression induced by TNF-and lipopolysaccharide, through inhibitionof NF-B 112) . Metformin, a hypoglycemic agent, at therapeutically relevant concentrations reduced the expression of both RAGE and LOX-1 in a dose-dependent manner, with an associated reduction in intracellular ROS 113) . In aortas of streptozotocin-treated rats, the dietary supplement taurine improved vascular endothelial dysfunction, an effect possibly associated with down-regulation of LOX-1 expression via antioxidative activity 114) . A number of studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduced total LDL cholesterol levels and exerted a cardioprotective effect.
Pretreatment of ECs with simvastatin or atorvastatin reduced the oxLDL-induced expression of LOX-1 as well as adhesion molecules. Both statins inhibited the activation of NF-B induced by oxLDL 81) ; the effect of statins on LOX-1 expression is associated with an increase in PKB activity 115) . The same treatments reduced the oxLDL-induced downregulation of eNOS expression and activation of MAPK 83) . The inhibitory effect on LOX-1 and subsequently MAPK activity provides a potential mechanism of beneficial effects of statins beyond the lowering of cholesterol levels.
In the aorta of hypercholesterolemic rabbits, benidipine, a dihydropyridine-type calcium channel blocker, significantly prevented the up-regulation of VCAM-1 mRNA expression and tended to inhibit LOX-1 mRNA expression, while pravastatin significantly prevented the up-regulation of both VCAM-1 and LOX-1 mRNA expression 116) . Moreover, aspirin and salicylate (but not indomethacin) reduced oxLDL-mediated LOX-1 expression in a dose-and time-dependent fashion 117) . Co-treatment with aspirin and pravastatin synergistically reduced platelet LOX-1 expression, by favorably affecting ROS and NO's release from activated platelets 118) . Taken together, these studies provide evidence that LOX-1 expression can be modulated by various pharmacological treatments and could thus represent an attractive target for therapeutic intervention to limit vascular injury and its long-term effects.
Conclusion and Future Perspectives
The axis between LOX-1 and its ligands is an etiological factor that contributes to the atherosclerotic process. The experimental evidence gathered thus far demonstrates that ligand-LOX-1 interaction can alter cell phenotype in a pro-atherogenic sense, so that cells become dysfunctional and more prone to cellular damage and even death. Studies with transgenic and KO mouse models and LOX-1 association with the instability of plaques have in part confirmed the pathogenic role of LOX-1 in atherosclerosis. Therefore, although LOX-1 could represent a valid target for therapeutic intervention in cardiovascular disease and stroke, continued studies on transgenic and KO mice are needed to help us understand not only what this particular receptor does, but also what it does not do.
Indeed, clinical observations do not yet convincingly support the proposed central role of LOX-1 in experimental atherosclerosis and raise the question of whether findings made in animal models, particularly in KO mouse models, can easily be translated to human disease.
Truly, a limitation that applies to KO studies in general is worth considering. Since KO mice lack the targeted gene product not only in the tissue studied, but globally and throughout development, they have many chances to alter the expression of other functionally related genes. Thus, these studies may reveal more about the ability of mice to compensate developmentally for the absence of a specific protein than about the role of the protein in normal adult tissues. Until these issues are resolved, the potential utility of drugs that perturb LOX-1 activity to prevent vascular disease remains unclear.
